Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...
With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...
Eisai, Eli Lilly didn’t disclose heightened brain injury risk to Alzheimer’s trial patients: NYT
A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...
After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Lundbeck is slashing the book value of its $250 million Abide Therapeutics buyout in response to phase 1 data that triggered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback